Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: implications for pathogenesis
✍ Scribed by Marie T. Bakowski; Philip Prescott
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 243 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1053-8569
No coin nor oath required. For personal study only.
✦ Synopsis
Sixteen pathologically con®rmed and 14 suspected cases of a new disease entity, ®brosing colonopathy, have been described in the UK and the US in children with cystic ®brosis since 1991. The patterns of use of pancreatic enzyme supplements in cases were compared with use in controls and in the market, in the 2 years prior to surgery for ®brosing colonopathy or the equivalent date in controls. The disease was only found in children with cystic ®brosis who had received brands of pancreatic enzyme supplement coated with methacrylic acid copolymer, for a period of at least 6 months. The risk was dose-related. No cases could be identi®ed in children who had only received other pancreatic enzyme formulations, irrespective of the strength of the formulation or the dose.